Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen has completed its acquisition of Ilypsa, a private company developing non-absorbed drugs for diabetes and inflammatory diseases.
Subscribe to our email newsletter
The transaction provides Amgen with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on hemodialysis.
The deal was originally announced June 4.